Life Biosciences
Stub active Updated Apr 12, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Life Biosciences is a Boston-based biotechnology company developing cellular rejuvenation therapies using its proprietary Partial Epigenetic Reprogramming (PER) platform 1. The company’s lead program ER-100 is in Phase 1 clinical trials for optic neuropathies including glaucoma and NAION 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-08 | Series D | $80M | Undisclosed (fully subscribed by existing and new investors) | — 123 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
Jerry McLaughlin, CEO: “We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging” 13.
Jerry McLaughlin, CEO: “This support enables us to advance our lead program, ER-100, through key clinical milestones while continuing the expansion of our pipeline” 3.
Sources
-
GlobeNewsWire, “Life Biosciences Secures $80 Million Series D Financing,” April 8, 2026. https://www.globenewswire.com/news-release/2026/04/08/3270043/0/en/Life-Biosciences-Secures-80-Million-Series-D-Financing.html↩↩↩↩
-
FinSMEs, “Life Biosciences Raises $80M in Series D Funding,” April 2026. https://www.finsmes.com/2026/04/life-biosciences-raises-80m-in-series-d-funding.html↩↩
-
Life Biosciences, “Life Biosciences Secures $80 Million Series D Financing,” April 8, 2026, accessed July 2026. https://www.lifebiosciences.com/life-biosciences-secures-80-million-series-d-financing/↩↩↩